XML 85 R60.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair value of financial instruments and investments - Summary of changes in the fair value of the Company's Level 3 valuation (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Stock Appreciation Rights (SARs)    
Changes in the fair value of warrant liability    
Beginning balance $ 3,814  
Ending balance 3,186 $ 3,814
Significant unobservable inputs (level 3) | Stock Appreciation Rights (SARs)    
Changes in the fair value of warrant liability    
Beginning balance 3,814 1,665
Additions 0 0
Change in fair value 3,187 4,140
Payments (3,815) (1,991)
Ending balance 3,186 3,814
Significant unobservable inputs (level 3) | Agilis    
Changes in the fair value of warrant liability    
Ending balance 65,800  
Liability, Development and Regulatory Milestone | Agilis    
Changes in the fair value of warrant liability    
Beginning balance 257,040  
Ending balance 290,500 257,040
Liability, Development and Regulatory Milestone | Significant unobservable inputs (level 3) | BioElectron | Commitments    
Changes in the fair value of warrant liability    
Beginning balance 257,040 0
Additions 0 263,500
Change in fair value 33,460 (6,460)
Payments 0 0
Ending balance 290,500 257,040
Liability, Net Sales Milestones and Royalties | Agilis    
Changes in the fair value of warrant liability    
Beginning balance 53,200  
Ending balance 65,800 53,200
Liability, Net Sales Milestones and Royalties | Significant unobservable inputs (level 3) | BioElectron    
Changes in the fair value of warrant liability    
Beginning balance 53,200 0
Additions 0 27,000
Change in fair value 12,600 26,200
Payments 0 0
Ending balance $ 65,800 $ 53,200